Positron Emission Tomography/Computed Tomography with <sup>89</sup>Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Loading...
Embargo End Date
ICR Authors
Authors
Hekman, MCH
Rijpkema, M
Aarntzen, EH
Mulder, SF
Langenhuijsen, JF
Oosterwijk, E
Boerman, OC
Oyen, WJG
Mulders, PFA
Rijpkema, M
Aarntzen, EH
Mulder, SF
Langenhuijsen, JF
Oosterwijk, E
Boerman, OC
Oyen, WJG
Mulders, PFA
Document Type
Journal Article
Date
2018-09
Date Accepted
2018-04-19
Abstract
Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of <sup>89</sup>Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of <sup>89</sup>Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with <sup>89</sup>Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, <sup>89</sup>Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that <sup>89</sup>Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion.Patient summary Positron emission tomography/computed tomography imaging with <sup>89</sup>Zr-girentuximab can be a valuable diagnostic tool to identify clear cell renal cell carcinoma.
Citation
European urology, 2018, 74 (3), pp. 257 - 260
Source Title
Publisher
ISSN
0302-2838
eISSN
1873-7560
Collections
Research Team
Translational Molecular Imaging